Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Branched-chain amino acids (BCAAs) have been studied as a nutritional intervention in individuals with Acquired Immune Deficiency Syndrome (AIDS), primarily due to their role in protein synthesis and the prevention of muscle wasting. People with AIDS often experience muscle wasting (cachexia) and malnutrition, which have significant negative impacts on morbidity and mortality. Some clinical studies, including small randomized controlled trials and observational reports, have explored whether BCAA supplementation can help preserve lean body mass or improve nutritional status in this population. The rationale is that BCAAs (leucine, isoleucine, and valine) are essential amino acids that may help stimulate muscle protein synthesis, particularly in the context of chronic illness and malnutrition. However, the scientific evidence supporting the use of BCAAs specifically for AIDS is limited and inconclusive. While some studies have shown modest improvements in nitrogen balance or lean body mass, these effects are not consistently demonstrated, and the clinical significance remains uncertain. Major clinical guidelines do not currently recommend BCAA supplementation as a standard therapy for AIDS-associated wasting, focusing instead on comprehensive nutritional support and antiretroviral therapy. Overall, while there is a scientific rationale and some preliminary research, the evidence base is weak (rated 2/5), and BCAA supplementation is not considered a primary or well-supported treatment for AIDS.

More about BCAA
More about Acquired Immune Deficiency Syndrome

Other ingredients used for Acquired Immune Deficiency Syndrome

Other health conditions supported by BCAA

Products containing BCAA